Newsletter | July 1, 2025

07.01.25 -- Will Genome Modifications Define Next-Gen AAV Vectors?

SPONSOR

Webinar: Solving the Inhalation Puzzle: A CDMO's Guide to Dry Powder Development

Dry powders for inhalation (DPIs) represent a versatile delivery platform. However, there are key factors such as required dosage and desired release profiles that dictate the development approach for DPIs. Join Lonza for a webinar that will highlight the key aspects in the product development of inhalation and nasal dry powder products from a CDMO perspective. Click here to learn more.

FEATURED EDITORIAL

Will Genome Modifications Define Next-Gen AAV Vectors?

AAV vectors composed of naturally occurring capsids are suboptimal. Gentle genetic alterations hold promise for safer, more efficient therapy.

INDUSTRY INSIGHTS

Nonclinical Studies In Cell And Gene Therapy

Looking for best practices and expert tips on how to address challenges and improve study efficiency in nonclinical gene therapy studies? Check out this scientific journal today!

Simultaneous Spray Drying For Combination Dry Powder Inhaler Formulations

Three combination case studies are demonstrated, in which bevacizumab is paired with erlotinib, cisplatin, or paclitaxel in a dry powder inhaler formulation.

Nitrosamine Analysis: Solutions For Risk Management And Analytical Testing

Testing for nitrosamines is essential in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and drug products to ensure safety and compliance.

Analysis Of DNA Integrity And Stability Using Digital PCR

Digital PCR offers precise, inhibitor-resistant DNA quantification and genome integrity assessment. Discover how this method enhances accuracy and reproducibility.

Formulation Scientist Shares What Drug Development Teams Should Never Do

Learn why transportation testing is critical to drug development — and how proactive planning can protect your product and investment from costly setbacks.

SOLUTIONS

PBPK Predictive Modeling Services